Legend Biotech Begins CEO Succession

Legend Biotech disclosed that Ying Huang resigned as chief executive officer and a director, effective July 24, after notifying the board on July 22. He is expected to advise the company through August. The…

Legend Biotech disclosed that Ying Huang resigned as chief executive officer and a director, effective July 24, after notifying the board on July 22. He is expected to advise the company through August. The…

Faron Pharmaceuticals reported the first overall-survival cut from 21 treatment-naïve higher-risk MDS patients receiving bexmarilimab plus azacitidine in the Phase 1/2 BEXMAB study. After 14.9 months of median follow-up, median overall survival was not…

A July 26 British Journal of Cancer study linked elevated HDAC6 expression with relapse in pediatric and adult B-ALL cohorts and showed that pharmacologic inhibition or shRNA depletion reduced CXCL12-driven actin remodeling, endothelial migration,…

argenx agreed to acquire Forte Biosciences for $77 per share in cash, representing approximately $2.2 billion in equity value. The transaction is funded from cash on hand, is not financing-contingent, and is expected to…

Tessera Therapeutics appointed Joseph Romanelli as president and chief executive officer, succeeding Michael Severino, who had led the Flagship-founded Gene Writing company since June 2022. Romanelli also joins Tessera’s board and Flagship Pioneering as…

FDA expanded Casgevy to patients aged two years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia, lowering the prior age threshold from 12 years. The July 1 approval…

A peer-reviewed multicenter phase 3 study from China compared azacitidine plus chidamide and CHOP with CHOP alone in 128 previously untreated patients with peripheral T-cell lymphoma. The experimental regimen did not significantly improve overall…

A peer-reviewed Science Immunology study integrated whole-genome germline sequencing from more than 200 lymphoma patients treated with axicabtagene ciloleucel in ZUMA-1 and ZUMA-7 with clinical biomarkers and functional CAR-T experiments. Putatively deleterious STXBP2 variants…

The LEO CReWE study analyzed 1,504 patients with relapsed or refractory large B-cell lymphoma treated from 2002 through 2022. Although autologous transplantation or CAR-T was planned for 65% at second line, only 31% received…

Europe’s medicines committee recommended Icotyde, or icotrokinra, for adults and adolescents aged 12 years and older weighing at least 40 kilograms with moderate-to-severe plaque psoriasis. The July 24 opinion covers a once-daily oral peptide…